INCB-057643
| CAS | 1820889-23-3 |
| 分子式 | C20H21N3O5S |
| 分子量 | 415.46 |
| 储存条件 | -20℃ |
| 纯度 | ≥98% |
| 单位 | 瓶 |
| SMILES | O=C1C(C)(C)OC2=C(C3=CN(C)C(C4=C3C=CN4)=O)C=C(S(=O)(C)=O)C=C2N1C |
| 靶点 | BET，Epigenetic Reader Domain |
| 规格 | 2mg 5mg |
Tocris
| 货号 | 产品名称 | 包装 | 品牌 |
| 2143-50MG | SCS | 50 mg | Tocris |
| 2144-1MG | R18 | 1 mg | Tocris |
| 2145-100UG | Difopein | 100 ug | Tocris |
| 2146-10MG | MRS 2578 | 10 mg | Tocris |
| 2146-50MG | MRS 2578 | 50 mg | Tocris |
| 2147-50MG | Nicorandil | 50 mg | Tocris |
| 2148-10MG | (±)-McN 5652 | 10 mg | Tocris |
| 2148-50MG | (±)-McN 5652 | 50 mg | Tocris |
| 2150-10MG | nTZDpa | 10 mg | Tocris |
| 2150-50MG | nTZDpa | 50 mg | Tocris |
| 2151-10MG | API-2 | 10 mg | Tocris |
| 2152-10MG | NSC 625987 | 10 mg | Tocris |
| 2152-50MG | NSC 625987 | 50 mg | Tocris |
| 2154-10MG | ZD 2079 | 10 mg | Tocris |
| 2154-50MG | ZD 2079 | 50 mg | Tocris |
| 2155-10MG | NTNCB hydrochloride | 10 mg | Tocris |
| 2155-50MG | NTNCB hydrochloride | 50 mg | Tocris |
| 2156-10MG | Embelin | 10 mg | Tocris |
| 2156-50MG | Embelin | 50 mg | Tocris |
| 2157-1MG | MRS 2365 | 1 mg | Tocris |
| 2158-1MG | MRS 2279 | 1 mg | Tocris |
| 2159-1MG | MRS 2500 tetraammonium salt | 1 mg | Tocris |
| 2160-10MG | Bax channel blocker | 10 mg | Tocris |
| 2160-50MG | Bax channel blocker | 50 mg | Tocris |
| 2161-10MG | NSC 23766 | 10 mg | Tocris |
| 2161-50MG | NSC 23766 | 50 mg | Tocris |
| 2162-10MG | INCA-6 | 10 mg | Tocris |
| 2162-50MG | INCA-6 | 50 mg | Tocris |
| 2163-1MG | Z-VAD-FMK | 1 mg | Tocris |
| 2164-1MG | Z-YVAD-FMK | 1 mg | Tocris |
| 2165-1MG | Z-VDVAD-FMK | 1 mg | Tocris |
| 2166-1MG | Z-DEVD-FMK | 1 mg | Tocris |
| 2167-1MG | Z-WEHD-FMK | 1 mg | Tocris |
| 2168-1MG | Z-DQMD-FMK | 1 mg | Tocris |
| 2169-1MG | Z-VEID-FMK | 1 mg | Tocris |
| 2172-10MG | AZ 10417808 | 10 mg | Tocris |
| 2172-50MG | AZ 10417808 | 50 mg | Tocris |
| 2173-10MG | WAY 629 hydrochloride | 10 mg | Tocris |
| 2173-50MG | WAY 629 hydrochloride | 50 mg | Tocris |
| 2174-10MG | Hispidulin | 10 mg | Tocris |
| 2175-10MG | Tetrabenazine | 10 mg | Tocris |
| 2175-50MG | Tetrabenazine | 50 mg | Tocris |
| 2176-10MG | BVT 948 | 10 mg | Tocris |
| 2176-50MG | BVT 948 | 50 mg | Tocris |
| 2177-1MG | BVD 10 | 1 mg | Tocris |
| 2178-1SET | Cannabinoid CB1 Receptor Tocriset™ | 1 Set | Tocris |
| 2180-1SET | Endocannabinoid Tocriset™ | 1 Set | Tocris |
| 2181-1SET | Vanilloid TRPV1 Receptor Tocriset™ | 1 Set | Tocris |
| 2182-50UG | Anti-phospho-NR2A (Ser1232) unphosphorylated blocking peptide | 50 ug | Tocris |
| 2183-10MG | ZK 164015 | 10 mg | Tocris |
| 2183-50MG | ZK 164015 | 50 mg | Tocris |
| 2184-10MG | SN-6 | 10 mg | Tocris |
| 2184-50MG | SN-6 | 50 mg | Tocris |
| 2185-10MG | NSC 146109 hydrochloride | 10 mg | Tocris |
| 2185-50MG | NSC 146109 hydrochloride | 50 mg | Tocris |
| 2186-10MG | CMPD-1 | 10 mg | Tocris |
| 2186-50MG | CMPD-1 | 50 mg | Tocris |
| 2187-10MG | NS 3763 | 10 mg | Tocris |
| 2187-50MG | NS 3763 | 50 mg | Tocris |
| 2188-1MG | Ro 0437626 | 1 mg | Tocris |
| 2188-10MG | Ro 0437626 | 10 mg | Tocris |
| 2190-10MG | SR 27897 | 10 mg | Tocris |
| 2190-50MG | SR 27897 | 50 mg | Tocris |
| 2191-50MG | S-Trityl-L-cysteine | 50 mg | Tocris |
| 2192-50MG | 4-HQN | 50 mg | Tocris |
| 2193-10MG | Carmoxirole hydrochloride | 10 mg | Tocris |
| 2193-50MG | Carmoxirole hydrochloride | 50 mg | Tocris |
| 2194-10MG | R 59-022 | 10 mg | Tocris |
| 2194-50MG | R 59-022 | 50 mg | Tocris |
| 2195-10MG | Eliprodil | 10 mg | Tocris |
| 2195-50MG | Eliprodil | 50 mg | Tocris |
| 2196-10MG | 3-MATIDA | 10 mg | Tocris |
| 2196-50MG | 3-MATIDA | 50 mg | Tocris |
| 2197-10MG | L-755,507 | 10 mg | Tocris |
| 2197-50MG | L-755,507 | 50 mg | Tocris |
| 2198-10MG | Mibefradil dihydrochloride | 10 mg | Tocris |
| 2198-50MG | Mibefradil dihydrochloride | 50 mg | Tocris |
| 2199-10MG | CGP 71683 hydrochloride | 10 mg | Tocris |
| 2199-50MG | CGP 71683 hydrochloride | 50 mg | Tocris |
| 2200-10MG | PD 160170 | 10 mg | Tocris |
| 2200-50MG | PD 160170 | 50 mg | Tocris |
| 2201-10MG | PNU 22394 hydrochloride | 10 mg | Tocris |
| 2201-50MG | PNU 22394 hydrochloride | 50 mg | Tocris |
| 2202-10MG | Zatebradine hydrochloride | 10 mg | Tocris |
| 2202-50MG | Zatebradine hydrochloride | 50 mg | Tocris |
| 2203-10MG | PALDA | 10 mg | Tocris |
| 2204-10MG | STEARDA | 10 mg | Tocris |
| 2206-10MG | 2-Palmitoylglycerol | 10 mg | Tocris |
| 2207-1MG | PDZ1 Domain inhibitor peptide | 1 mg | Tocris |
| 2208-10MG | LY 255283 | 10 mg | Tocris |
| 2208-50MG | LY 255283 | 50 mg | Tocris |
| 2211-50MG | Carcinine ditrifluoroacetate | 50 mg | Tocris |
| 2213-10MG | N20C hydrochloride | 10 mg | Tocris |
| 2213-50MG | N20C hydrochloride | 50 mg | Tocris |
| 2214-10MG | ABT 724 trihydrochloride | 10 mg | Tocris |
| 2214-50MG | ABT 724 trihydrochloride | 50 mg | Tocris |
| 2215-1MG | Urotensin II-related peptide | 1 mg | Tocris |
| 2216-1MG | des-His1-[Glu9]-Glucagon (1-29) amide | 1 mg | Tocris |
| 2217-10MG | (±)-HIP-A | 10 mg | Tocris |
| 2218-10MG | (±)-HIP-B | 10 mg | Tocris |
| 2220-1MG | FURA-2AM | 1 mg | Tocris |
| 2221-1MG | Rac1 Inhibitor W56 | 1 mg | Tocris |
| 2222-1MG | Rac1 Inhibitor F56, control peptide | 1 mg | Tocris |
| 2224-10MG | MNI-caged-NMDA | 10 mg | Tocris |
| 2225-10MG | MNI caged kainic acid | 10 mg | Tocris |
| 2226-1MG | Flutax 1 | 1 mg | Tocris |
| 2227-10MG | CI 976 | 10 mg | Tocris |
| 2227-50MG | CI 976 | 50 mg | Tocris |
| 2228-50MG | Leflunomide | 50 mg | Tocris |
| 2229-10MG | GW 0742 | 10 mg | Tocris |
| 2229-50MG | GW 0742 | 50 mg | Tocris |
| 2231-100UG | Anti-CB2 | 100 ug | Tocris |
| 2233-100UG | Anti-TRPV1 | 100 ug | Tocris |
| 2235-1MG | L803 | 1 mg | Tocris |
| 2236-1MG | TCS 183 | 1 mg | Tocris |
| 2237-10MG | BRL 50481 | 10 mg | Tocris |
| 2237-50MG | BRL 50481 | 50 mg | Tocris |
| 2238-10MG | GW 441756 | 10 mg | Tocris |
| 2238-50MG | GW 441756 | 50 mg | Tocris |
| 2239-10MG | GW 583340 dihydrochloride | 10 mg | Tocris |
| 2239-50MG | GW 583340 dihydrochloride | 50 mg | Tocris |
| 2241-10MG | DMAB-anabaseine dihydrochloride | 10 mg | Tocris |
| 2241-50MG | DMAB-anabaseine dihydrochloride | 50 mg | Tocris |
| 2242-100MG | Octopamine hydrochloride | 100 mg | Tocris |
| 2243-1SET | MEK Inhibitor Tocriset™ | 1 Set | Tocris |
| 2244-1SET | p38 MAPK Inhibitor Tocriset™ | 1 Set | Tocris |
| 2250-1MG | SL 0101-1 | 1 mg | Tocris |
| 2251-50MG | Cisplatin | 50 mg | Tocris |
| 2252-10MG | Doxorubicin hydrochloride | 10 mg | Tocris |
| 2252-50MG | Doxorubicin hydrochloride | 50 mg | Tocris |
| 2253-1MG | Go 6976 | 1 mg | Tocris |
| 2254-10MG | ACDPP hydrochloride | 10 mg | Tocris |
| 2254-50MG | ACDPP hydrochloride | 50 mg | Tocris |
| 2255-10MG | CGS 9343B | 10 mg | Tocris |
| 2256-1MG | L803-mts | 1 mg | Tocris |
| 2257-1MG | GIP (1-39) | 1 mg | Tocris |
| 2258-1MG | GLP-2 (human) | 1 mg | Tocris |
| 2259-1MG | GLP-2 (rat) | 1 mg | Tocris |
| 2260-1MG | [Des-octanoyl]-Ghrelin (human) | 1 mg | Tocris |
| 2261-10MG | L-692,585 | 10 mg | Tocris |
| 2262-1MG | WRW4 | 1 mg | Tocris |
| 2264-1MG | Motilin (human, porcine) | 1 mg | Tocris |
| 2265-1MG | Lyn peptide inhibitor | 1 mg | Tocris |
| 2266-10MG | DY131 | 10 mg | Tocris |
| 2266-50MG | DY131 | 50 mg | Tocris |
| 2267-200UG | Lactacystin | 200 ug | Tocris |
| 2268-10MG | NNC 55-0396 dihydrochloride | 10 mg | Tocris |
| 2270-10MG | SCH 58261 | 10 mg | Tocris |
| 2270-50MG | SCH 58261 | 50 mg | Tocris |
| 2271-10MG | GW 6471 | 10 mg | Tocris |
| 2271-50MG | GW 6471 | 50 mg | Tocris |
| 2272-1MG | Ro 08-2750 | 1 mg | Tocris |
| 2272-10MG | Ro 08-2750 | 10 mg | Tocris |
| 2272-50MG | Ro 08-2750 | 50 mg | Tocris |
| 2273-10MG | PMPA (NMDA antagonist) | 10 mg | Tocris |
| 2273-50MG | PMPA (NMDA antagonist) | 50 mg | Tocris |
| 2274-10MG | PPPA | 10 mg | Tocris |
| 2274-50MG | PPPA | 50 mg | Tocris |
| 2275-10MG | TBB | 10 mg | Tocris |
| 2275-50MG | TBB | 50 mg | Tocris |
| 2276-10MG | FPL 55712 | 10 mg | Tocris |
| 2277-10MG | MNI-caged-D-aspartate | 10 mg | Tocris |
| 2277-50MG | MNI-caged-D-aspartate | 50 mg | Tocris |
| 2280-50MG | Raloxifene hydrochloride | 50 mg | Tocris |
| 2281-10MG | 2′-MeCCPA | 10 mg | Tocris |
| 2282-10MG | Moxonidine hydrochloride | 10 mg | Tocris |
| 2282-50MG | Moxonidine hydrochloride | 50 mg | Tocris |
| 2284-10MG | SEW 2871 | 10 mg | Tocris |
| 2284-50MG | SEW 2871 | 50 mg | Tocris |
| 2285-1MG | Go 6983 | 1 mg | Tocris |
| 2285-10MG | Go 6983 | 10 mg | Tocris |
| 2287-1MG | K-252c | 1 mg | Tocris |
| 2288-10MG | O-1918 | 10 mg | Tocris |
| 2289-10MG | Lamotrigine isethionate | 10 mg | Tocris |
| 2289-50MG | Lamotrigine isethionate | 50 mg | Tocris |
| 2290-10MG | Sibutramine hydrochloride | 10 mg | Tocris |
| 2290-50MG | Sibutramine hydrochloride | 50 mg | Tocris |
| 2291-50MG | 1,2,3,4,5,6-Hexabromocyclohexane | 50 mg | Tocris |
| 2292-10MG | AQ-RA 741 | 10 mg | Tocris |
| 2292-50MG | AQ-RA 741 | 50 mg | Tocris |
| 2293-10MG | Zebularine | 10 mg | Tocris |
| 2294-10MG | Cordycepin | 10 mg | Tocris |
| 2295-10MG | (±)-Cloprostenol sodium salt | 10 mg | Tocris |
| 2296-10MG | Prostaglandin E2 | 10 mg | Tocris |
| 2297-10MG | Misoprostol | 10 mg | Tocris |
| 2299-10MG | SCH 39166 hydrobromide | 10 mg | Tocris |
| 2299-50MG | SCH 39166 hydrobromide | 50 mg | Tocris |
| 2301-10MG | T 0070907 | 10 mg | Tocris |
| 2301-50MG | T 0070907 | 50 mg | Tocris |
| 2302-10MG | Sanguinarine chloride | 10 mg | Tocris |
| 2302-50MG | Sanguinarine chloride | 50 mg | Tocris |
| 2303-10MG | PNU 282987 | 10 mg | Tocris |
| 2303-50MG | PNU 282987 | 50 mg | Tocris |
| 2304-10MG | Devazepide | 10 mg | Tocris |
| 2304-50MG | Devazepide | 50 mg | Tocris |
| 2305-50UG | Tautomycetin | 50 ug | Tocris |
| 2306-1MG | 15-deoxy-Δ-12,14-Prostaglandin J2 | 1 mg | Tocris |
| 2307-50UG | Leukotriene B4 | 50 ug | Tocris |
| 2308-10MG | Tabimorelin hemifumarate | 10 mg | Tocris |
| 2309-1MG | SR 142948 | 1 mg | Tocris |
| 2309-10MG | SR 142948 | 10 mg | Tocris |
| 2310-10MG | SR 49059 | 10 mg | Tocris |
| 2311-10MG | L-168,049 | 10 mg | Tocris |
| 2311-50MG | L-168,049 | 50 mg | Tocris |
| 2312-10MG | DNQX disodium salt | 10 mg | Tocris |
| 2312-50MG | DNQX disodium salt | 50 mg | Tocris |
| 2313-50MG | QX 314 chloride | 50 mg | Tocris |
| 2314-10MG | LOE 908 hydrochloride | 10 mg | Tocris |
| 2314-50MG | LOE 908 hydrochloride | 50 mg | Tocris |
| 2315-10MG | Immethridine dihydrobromide | 10 mg | Tocris |
| 2315-50MG | Immethridine dihydrobromide | 50 mg | Tocris |
| 2316-10MG | AMG 9810 | 10 mg | Tocris |
| 2316-50MG | AMG 9810 | 50 mg | Tocris |
| 2318-50MG | Pravastatin sodium salt | 50 mg | Tocris |
| 2319-1MG | CALP2 | 1 mg | Tocris |
| 2320-1MG | TCS 184 | 1 mg | Tocris |
| 2321-1MG | CALP3 | 1 mg | Tocris |
| 2322-10MG | BTS 54-505 hydrochloride | 10 mg | Tocris |
| 2322-50MG | BTS 54-505 hydrochloride | 50 mg | Tocris |
| 2324-10MG | Necrostatin-1 | 10 mg | Tocris |
| 2324-50MG | Necrostatin-1 | 50 mg | Tocris |
| 2327-10MG | WIN 55,212-3 mesylate | 10 mg | Tocris |
| 2327-50MG | WIN 55,212-3 mesylate | 50 mg | Tocris |
| 2329-10MG | Ro 10-5824 dihydrochloride | 10 mg | Tocris |
| 2329-50MG | Ro 10-5824 dihydrochloride | 50 mg | Tocris |
| 2330-10MG | DMP 543 | 10 mg | Tocris |
| 2330-50MG | DMP 543 | 50 mg | Tocris |
| 2333-10MG | JNJ 16259685 | 10 mg | Tocris |
| 2333-50MG | JNJ 16259685 | 50 mg | Tocris |
| 2334-1MG | D15 | 1 mg | Tocris |
| 2335-50UG | Anti-TRPV1 blocking peptide | 50 ug | Tocris |
| 2336-50UG | Anti-phospho-GluR1 (Ser831) unphosphorylated blocking peptide | 50 ug | Tocris |
| 2337-10MG | Trequinsin hydrochloride | 10 mg | Tocris |
| 2338-10MG | MK 571 | 10 mg | Tocris |
| 2339-1MG | WEB 2086 | 1 mg | Tocris |
| 2339-10MG | WEB 2086 | 10 mg | Tocris |
| 2341-10MG | A 80426 mesylate | 10 mg | Tocris |
| 2341-50MG | A 80426 mesylate | 50 mg | Tocris |
| 2342-10MG | 4-Methylhistamine dihydrochloride | 10 mg | Tocris |
| 2342-50MG | 4-Methylhistamine dihydrochloride | 50 mg | Tocris |
| 2344-10MG | CGH 2466 dihydrochloride | 10 mg | Tocris |
| 2344-50MG | CGH 2466 dihydrochloride | 50 mg | Tocris |
| 2345-10MG | ZK 200775 | 10 mg | Tocris |
| 2345-50MG | ZK 200775 | 50 mg | Tocris |
| 2347-10MG | Salubrinal | 10 mg | Tocris |
| 2348-10MG | Gavestinel | 10 mg | Tocris |
| 2348-50MG | Gavestinel | 50 mg | Tocris |
| 2349-10MG | Dihydro-β-erythroidine hydrobromide | 10 mg | Tocris |
| 2349-50MG | Dihydro-β-erythroidine hydrobromide | 50 mg | Tocris |
| 2355-100UG | Anti-VEGF (Clone VG-1) | 100 ug | Tocris |
| 2356-100UG | Anti-Cdk1 and Cdk2 (Clone AN21.2) | 100 ug | Tocris |
| 2357-100UG | Anti-Cdk2 (Clone AN4.3) | 100 ug | Tocris |
| 2358-100UG | Anti-c-Jun (Clone CJ 4C4/1) | 100 ug | Tocris |
| 2360-100UG | Anti-N-Myc (Clone NMYC-1) | 100 ug | Tocris |
| 2361-100UG | Anti-EGFR (Clone EGFR1) | 100 ug | Tocris |
| 2362-100UG | Anti-EGFR (Clone F4) | 100 ug | Tocris |
| 2363-100UG | Anti-FGF-3 (Clone MSD1) | 100 ug | Tocris |
| 2364-100UG | Anti-NCAM (Clone ERIC-1) | 100 ug | Tocris |
| 2366-100UG | Anti-p14ARF (Clone 4C6/4) | 100 ug | Tocris |
| 2367-100UG | Anti-PKC α (Clone MC5) | 100 ug | Tocris |
| 2368-100UG | Anti-PIP2 (Clone PIP2 2C11) | 100 ug | Tocris |
| 2369-100UG | Anti-p53 (Clone pAB 240) | 100 ug | Tocris |
| 2370-1MG | Bombinakinin-GAP | 1 mg | Tocris |
| 2371-1MG | Bombinakinin M | 1 mg | Tocris |
| 2372-10MG | ABT 702 dihydrochloride | 10 mg | Tocris |
| 2373-10MG | T 0901317 | 10 mg | Tocris |
| 2373-50MG | T 0901317 | 50 mg | Tocris |
| 2374-10MG | GW 405833 | 10 mg | Tocris |
| 2375-100UG | Anti-p53 (Clone pAB 1802) | 100 ug | Tocris |
| 2376-100UG | Anti-p53 (Clone DO-2) | 100 ug | Tocris |
| 2378-100UG | Anti-p53 (Clone pAB 1801) | 100 ug | Tocris |
| 2379-100UG | Anti-c-erbB4 (Clone HFR1) | 100 ug | Tocris |
| 2380-100UG | Anti-c-erbB3 (Clone RTJ2) | 100 ug | Tocris |
| 2381-100UG | Anti-phospho-MDM2 (Ser186) (Clone 2G2) | 100 ug | Tocris |
| 2382-10MG | EMD 386088 hydrochloride | 10 mg | Tocris |
| 2382-50MG | EMD 386088 hydrochloride | 50 mg | Tocris |
| 2383-10UG | Bryostatin 1 | 10 ug | Tocris |
| 2385-10MG | AMN 082 dihydrochloride | 10 mg | Tocris |
| 2385-50MG | AMN 082 dihydrochloride | 50 mg | Tocris |
| 2386-10MG | Fenobam | 10 mg | Tocris |
| 2386-50MG | Fenobam | 50 mg | Tocris |
| 2387-10MG | LY 320135 | 10 mg | Tocris |
| 2387-50MG | LY 320135 | 50 mg | Tocris |
| 2388-50UG | Anti-CB2 blocking peptide | 50 ug | Tocris |
| 2390-10MG | LY 456236 hydrochloride | 10 mg | Tocris |
| 2390-50MG | LY 456236 hydrochloride | 50 mg | Tocris |
| 2391-500UG | Astressin 2B | 500 ug | Tocris |
| 2392-10MG | JTE 013 | 10 mg | Tocris |
| 2394-10MG | SDZ NKT 343 | 10 mg | Tocris |
| 2395-10MG | Sertraline hydrochloride | 10 mg | Tocris |
| 2395-50MG | Sertraline hydrochloride | 50 mg | Tocris |
| 2396-10MG | Glimepiride | 10 mg | Tocris |
| 2396-50MG | Glimepiride | 50 mg | Tocris |
| 2397-10MG | Eplerenone | 10 mg | Tocris |
| 2397-50MG | Eplerenone | 50 mg | Tocris |
| 2398-10MG | SNAP 5089 | 10 mg | Tocris |
| 2398-50MG | SNAP 5089 | 50 mg | Tocris |
| 2399-10MG | Indorenate hydrochloride | 10 mg | Tocris |
| 2399-50MG | Indorenate hydrochloride | 50 mg | Tocris |
| 2400-10MG | FK 888 | 10 mg | Tocris |
| 2402-10MG | MRS 2211 | 10 mg | Tocris |
| 2402-50MG | MRS 2211 | 50 mg | Tocris |
| 2403-10MG | MRS 3777 hemioxalate | 10 mg | Tocris |
| 2404-50MG | Ambroxol hydrochloride | 50 mg | Tocris |
| 2406-1MG | FTI 276 | 1 mg | Tocris |
| 2407-1MG | FTI 277 | 1 mg | Tocris |
| 2408-10MG | Ro 90-7501 | 10 mg | Tocris |
| 2408-50MG | Ro 90-7501 | 50 mg | Tocris |
| 2409-50MG | Conessine | 50 mg | Tocris |
| 2410-10MG | L-371,257 | 10 mg | Tocris |
| 2411-1MG | A-71623 | 1 mg | Tocris |
| 2412-10MG | BIBO 3304 trifluoroacetate | 10 mg | Tocris |
| 2412-50MG | BIBO 3304 trifluoroacetate | 50 mg | Tocris |
| 2414-1MG | H 1152 dihydrochloride | 1 mg | Tocris |
| 2415-10MG | HA 1100 hydrochloride | 10 mg | Tocris |
| 2416-1MG | BIBX 1382 dihydrochloride | 1 mg | Tocris |
| 2416-10MG | BIBX 1382 dihydrochloride | 10 mg | Tocris |
| 2417-1MG | BIBU 1361 dihydrochloride | 1 mg | Tocris |
| 2417-10MG | BIBU 1361 dihydrochloride | 10 mg | Tocris |
| 2418-5MG | LY 303511 | 5 mg | Tocris |
| 2420-1MG | [Pyr1]-Apelin-13 | 1 mg | Tocris |
| 2421-10MG | Scriptaid | 10 mg | Tocris |
| 2421-50MG | Scriptaid | 50 mg | Tocris |
| 2422-1MG | AKTide-2T | 1 mg | Tocris |
| 2423-1MG | DAPTA | 1 mg | Tocris |
| 2424-1MG | Amyloid β-peptide (1-40) (rat) | 1 mg | Tocris |
| 2425-500UG | Amyloid β-peptide (1-42) (rat) | 500 ug | Tocris |
| 2426-1MG | Apelin-36 (human) | 1 mg | Tocris |
| 2427-1MG | Apelin-36 (rat, mouse) | 1 mg | Tocris |
| 2429-10MG | Fexofenadine hydrochloride | 10 mg | Tocris |
| 2429-50MG | Fexofenadine hydrochloride | 50 mg | Tocris |
| 2430-1MG | GGTI 298 | 1 mg | Tocris |
| 2432-10MG | Anagrelide hydrochloride | 10 mg | Tocris |
| 2432-50MG | Anagrelide hydrochloride | 50 mg | Tocris |
| 2433-10MG | L-759,633 | 10 mg | Tocris |
| 2434-10MG | L-759,656 | 10 mg | Tocris |
| 2435-10MG | CCT 018159 | 10 mg | Tocris |
| 2435-50MG | CCT 018159 | 50 mg | Tocris |
| 2436-10MG | AC 55649 | 10 mg | Tocris |
| 2436-50MG | AC 55649 | 50 mg | Tocris |
| 2438-10MG | TMPH hydrochloride | 10 mg | Tocris |
| 2438-50MG | TMPH hydrochloride | 50 mg | Tocris |
| 2440-10MG | NNC 26-9100 | 10 mg | Tocris |
| 2441-10MG | JNJ 10191584 maleate | 10 mg | Tocris |
| 2441-50MG | JNJ 10191584 maleate | 50 mg | Tocris |
| 2442-10MG | CGP 53353 | 10 mg | Tocris |
| 2443-1MG | RITA | 1 mg | Tocris |
| 2443-10MG | RITA | 10 mg | Tocris |
| 2444-1MG | (1R,1’S,3’R/1R,1’R,3’S)-L-054,264 | 1 mg | Tocris |
| 2444-10MG | (1R,1’S,3’R/1R,1’R,3’S)-L-054,264 | 10 mg | Tocris |
| 2445-1MG | Obestatin (rat) | 1 mg | Tocris |
| 2446-10MG | AS 101 | 10 mg | Tocris |
| 2446-50MG | AS 101 | 50 mg | Tocris |
| 2447-10MG | Desmethyl-YM 298198 | 10 mg | Tocris |
| 2447-50MG | Desmethyl-YM 298198 | 50 mg | Tocris |
| 2448-10MG | YM 298198 hydrochloride | 10 mg | Tocris |
| 2448-50MG | YM 298198 hydrochloride | 50 mg | Tocris |
| 2450-10MG | NF 157 | 10 mg | Tocris |
| 2450-50MG | NF 157 | 50 mg | Tocris |
| 2451-10MG | LY 344864 hydrochloride | 10 mg | Tocris |
| 2451-50MG | LY 344864 hydrochloride | 50 mg | Tocris |
| 2452-1MG | LY 2183240 | 1 mg | Tocris |
| 2452-10MG | LY 2183240 | 10 mg | Tocris |
| 2453-10MG | LY 379268 | 10 mg | Tocris |
| 2453-50MG | LY 379268 | 50 mg | Tocris |
| 2456-10MG | Co 101244 hydrochloride | 10 mg | Tocris |
| 2456-50MG | Co 101244 hydrochloride | 50 mg | Tocris |
| 2457-10MG | Arcyriaflavin A | 10 mg | Tocris |
| 2458-10MG | ZM 447439 | 10 mg | Tocris |
| 2459-10MG | Tropisetron hydrochloride | 10 mg | Tocris |
| 2459-50MG | Tropisetron hydrochloride | 50 mg | Tocris |
| 2460-10MG | Lazabemide hydrochloride | 10 mg | Tocris |
| 2460-50MG | Lazabemide hydrochloride | 50 mg | Tocris |
| 2463-1MG | SCH 442416 | 1 mg | Tocris |
| 2463-10MG | SCH 442416 | 10 mg | Tocris |
| 2463-50MG | SCH 442416 | 50 mg | Tocris |
| 2464-5MG | TNP-ATP triethylammonium salt | 5 mg | Tocris |
| 2465-10MG | SDZ WAG 994 | 10 mg | Tocris |
| 2466-10MG | UK 14,304 tartrate | 10 mg | Tocris |
| 2466-50MG | UK 14,304 tartrate | 50 mg | Tocris |
| 2467-10MG | CGS 20625 | 10 mg | Tocris |
| 2467-50MG | CGS 20625 | 50 mg | Tocris |
| 2469-10MG | IBC 293 | 10 mg | Tocris |
| 2469-50MG | IBC 293 | 50 mg | Tocris |
| 2470-100MG | Nimesulide | 100 mg | Tocris |
| 2471-10MG | ER 27319 maleate | 10 mg | Tocris |
| 2471-50MG | ER 27319 maleate | 50 mg | Tocris |
| 2473-10MG | GW 4064 | 10 mg | Tocris |
| 2473-50MG | GW 4064 | 50 mg | Tocris |
| 2474-1MG | GW 3965 hydrochloride | 1 mg | Tocris |
| 2474-10MG | GW 3965 hydrochloride | 10 mg | Tocris |
| 2475-1MG | ZM 323881 hydrochloride | 1 mg | Tocris |
| 2475-10MG | ZM 323881 hydrochloride | 10 mg | Tocris |
| 2476-10MG | SR 11302 | 10 mg | Tocris |
| 2477-10MG | Proxyfan oxalate | 10 mg | Tocris |
| 2477-50MG | Proxyfan oxalate | 50 mg | Tocris |
| 2478-50MG | 2-Pyridylethylamine dihydrochloride | 50 mg | Tocris |
| 2479-10MG | JTE 907 | 10 mg | Tocris |
| 2479-50MG | JTE 907 | 50 mg | Tocris |
| 2481-10MG | JTC 801 | 10 mg | Tocris |
| 2481-50MG | JTC 801 | 50 mg | Tocris |
| 2483-1MG | Costunolide | 1 mg | Tocris |
| 2483-10MG | Costunolide | 10 mg | Tocris |
| 2484-10MG | (±)-AC 7954 hydrochloride | 10 mg | Tocris |
| 2484-50MG | (±)-AC 7954 hydrochloride | 50 mg | Tocris |
| 2485-1MG | Glycyl-H 1152 dihydrochloride | 1 mg | Tocris |
| 2489-10MG | C 75 | 10 mg | Tocris |
| 2489-50MG | C 75 | 50 mg | Tocris |
| 2490-10MG | (±)-Clopidogrel hydrochloride | 10 mg | Tocris |
| 2490-50MG | (±)-Clopidogrel hydrochloride | 50 mg | Tocris |
| 2491-10MG | Xaliproden hydrochloride | 10 mg | Tocris |
| 2491-50MG | Xaliproden hydrochloride | 50 mg | Tocris |
| 2492-10MG | MNITMT | 10 mg | Tocris |
| 2492-50MG | MNITMT | 50 mg | Tocris |
| 2493-10MG | VUF 5681 dihydrobromide | 10 mg | Tocris |
| 2493-50MG | VUF 5681 dihydrobromide | 50 mg | Tocris |
| 2494-10MG | VUF 8430 dihydrobromide | 10 mg | Tocris |
| 2494-50MG | VUF 8430 dihydrobromide | 50 mg | Tocris |
| 2495-10MG | Melperone hydrochloride | 10 mg | Tocris |
| 2495-50MG | Melperone hydrochloride | 50 mg | Tocris |
| 2496-1MG | DR 2313 | 1 mg | Tocris |
| 2496-10MG | DR 2313 | 10 mg | Tocris |
| 2496-50MG | DR 2313 | 50 mg | Tocris |
| 2498-10MG | PNU 120596 | 10 mg | Tocris |
| 2498-50MG | PNU 120596 | 50 mg | Tocris |
| 2499-1MG | ZM 306416 hydrochloride | 1 mg | Tocris |
| 2499-10MG | ZM 306416 hydrochloride | 10 mg | Tocris |
| 2500-10MG | Bay 59-3074 | 10 mg | Tocris |
| 2500-50MG | Bay 59-3074 | 50 mg | Tocris |
| 2501-10MG | Bay 36-7620 | 10 mg | Tocris |
| 2502-1MG | MRS 2693 trisodium salt | 1 mg | Tocris |
| 2503-10MG | (-)-Bicuculline methiodide | 10 mg | Tocris |
| 2503-50MG | (-)-Bicuculline methiodide | 50 mg | Tocris |
| 2504-50MG | Irsogladine maleate | 50 mg | Tocris |
| 2505-10MG | Nonactin | 10 mg | Tocris |
| 2506-10MG | SSR 69071 | 10 mg | Tocris |
| 2507-10MG | J 104129 fumarate | 10 mg | Tocris |
| 2508-10MG | Trap 101 | 10 mg | Tocris |
| 2508-50MG | Trap 101 | 50 mg | Tocris |
| 2509-10MG | Cardamonin | 10 mg | Tocris |
| 2509-50MG | Cardamonin | 50 mg | Tocris |
| 2510-10MG | Talniflumate | 10 mg | Tocris |
| 2510-50MG | Talniflumate | 50 mg | Tocris |
| 2511-5MG | APC 366 | 5 mg | Tocris |
| 2512-10MG | CGS 35066 | 10 mg | Tocris |
炎症小体诱导剂
炎症小体会被过量的微生物或无菌危险信号激活。微生物是多种PAMPs的来源，这些PAMPs由多个PRRs感知，而PRRs负责提供启动和激活信号（例如革兰氏阴性细菌可以传递LPS、dsDNA、鞭毛蛋白和毒素等信号分子）。无菌的危险信号可以是内源性，例如ATP和导致痛风的MSU晶体，或者是外源性，包括铝盐和石棉。InvivoGen提供了通过功能验证和内毒素测试的炎症小体诱导剂系列。
经典炎症小体诱导剂
ATP
细胞外三磷酸腺苷（ATP）与其嘌呤P2X7受体（P2X7R）结合后可触发NLRP3炎症小体的活化。这种ATP门控离子通道的快速开放可导致细胞内K+外排。K+外排被认为是诱导NLRP3激活最低限度所需要的细胞事件 [2, 69-71]。
Nigericin
尼日利亚菌素（Nigericin）是一种源自革兰氏阳性细菌吸水链霉菌（S. hygroscopicus）的微生物毒素。它可响应NLRP3炎症小体的激活，诱导IL-1β的释放 [2]。这种毒素似乎是利用其离子载体功能来活化NLRP3，从而允许细胞内K+跨膜外排 [70]。
现时尚未清楚在Nigericin刺激后的NLRP3活化是否依赖非选择性pannexin-1膜孔的形成 [34]。
MSU 和 CPPD 晶体
单钠尿酸盐（MSU）和二水焦磷酸钙盐（CPPD）晶体沉积在关节和关节周围组织中，它们分别可以导致痛风和假痛风的炎症症状。MSU和CPPD晶体已被描述为NLRP3炎症小体的无菌内源性诱导剂 [3]，通过内吞和溶酶体破裂可以触发K+外排，随后激活NLRP3 [70]。
Alum Hydroxide
氢氧化铝（Alum hydroxide）是铝盐的一种，又称明矾（Alum）,为NLRP3炎症小体的有效诱导剂 [38]。与MSU和CPPD晶体相似，氢氧化铝可以在溶酶体破裂和K+ 外排后激活NLRP3 [70]。
Poly(dA:dT)
Poly(dA:dT) 是poly(dA-dT):poly(dT-dA)的合成重复dsDNA序列。这种多靶点PRR激动剂在鼠源巨噬细胞中能够诱导AIM2炎症小体 [20]。在人源骨髓细胞中，AIM2的作用对感应胞质dsDNA的cGAS-STING-NLRP3的激活途径似乎是冗余的 [21]。
LFn-Needle 和 LFn-Rod
细胞内细菌III型或IV型分泌系统（T3SS或T4SS）的蛋白成分是NLRC4/NAIP炎症小体的诱导剂（见第9页）。InvivoGen提供来自泰国伯克霍尔德氏菌（B. thailandensis）和鼠伤寒沙门氏菌（S. thyphimurium）的T3SS针状（Needle）和内杆（Inner Rod）蛋白。这些蛋白融合到炭疽芽孢杆菌（B. anthracis）致死因子（lethal factor，LFn）的N-末端结构域。LFn-Needle 或 LFn-Rod 的融合蛋白与炭疽保护性抗原（PA）的组合分别称为 Needle-Tox 或 Rod-Tox [10]。PA能够介导LFn-Needle和LFn-Rod易位到细胞质中。
非经典炎症小体诱导剂
LPS-EK 和 LPS-EB脂多糖（LPS）来源于革兰氏阴性细菌，当其存在于哺乳动物细胞的细胞质时，会诱导CASP-11/4/5炎症小体的活化。LPS是由帮助脂多糖分子锚定在外膜上的脂质A（也称为内毒素）组成。不同的细菌种类的脂质A中会有不同的脂肪酰基链数量，这种差异会影响CASP-11/4/5的活化。LPS-EK（R型LPS）和 LPS-EB（S型LPS）是从大肠杆菌中纯化而成的，它们拥有六酰基化脂质A（即6条脂肪酸链），在转染后可有效激活人源CASP-4 /5和鼠源CASP-11。
大肠杆菌外膜囊泡（OMVs）
外膜囊泡（OMVs）由革兰氏阴性细菌（包括大肠杆菌）产生，是具有免疫原性的双层球形体。它们含有许多PAMPs，如LPS。由于大肠杆菌OMVs天然地被哺乳动物细胞内吞，因此无需使用转染试剂即可将LPS有效传递到胞浆中。它们可以有效触发CASP-11/4/5炎症小体。InvivoGen的大肠杆菌OMVs是从大肠杆菌BL21中纯化出来。
相关产品：
| 产品名称 | 炎症小体 | 规格 | 货号 |
| Alum Hydroxide | NLRP | 500 µl | tlrl-aloh |
| ATP | 1 g | tlrl-atpl | |
| MSU Crystals | 5 mg | tlrl-nig | |
| Nigericin | 10 mg | tlrl-nig |
| Poly(dA:dT) | AIM2 | 200 µg | tlrl-patn |
| LFn-Needle | NLRC4 | 5 µg | LFn-ndl |
| LFn-Rod | 50 µg | tlrl-rod | |
|
LPS-EB Ultrapure (E.coli O111:B4) |
CASP-11/4/5 | 5 x 10e6 EU | tlrl-3pelps |
|
LPS-EK Ultrapure (E.coli K12) |
1 mg | tlrl-peklps | |
| E. coli OMVs | 100 µg | tlrl-omv-1 |
如需购买炎症小体相关产品或了解更多技术问题，请咨询Invivogen中国代理商-上海金畔生物
Procyanidin B2；原花青素B2
| MDL | MFCD01861513 |
| 别名 | 原矢车菊素B2 |
| 英文名称 | Procyanidin B2 |
| CAS | 29106-49-8 |
| 分子式 | C30H26O12 |
| 分子量 | 578.52 |
| 纯度 | HPLC≥98% |
| 单位 | 瓶 |
| 生物活性 | Procyanidin B2 是一种天然黄酮类物质，具有抗肿瘤，抗氧化等作用。[1-3] |
| In Vitro | 原花青素B2显示对MCF-7细胞的抗增殖活性, IC50为19.21μM。然而, 原花青素B2对DNA梯形成没有影响[1]。原花青素B2 (0.1, 1, 2μM) 抑制人脐静脉内皮细胞 (HUVECs) 中含有3 (NLRP3) 炎性体的pyrin结构域的激活, 并且通过抑制AP-1活性来抑制这种作用, 并且可以通过抑制这种作用来消除这种作用。过表达c-Jun。原花青素B2 (2μM, 12小时) 也可降低HUVEC中的ROS [2]。 |
| In Vivo | 原花青素B2 (40, 20和10mg / kg, 口服) 保护免受脑缺血诱导的大鼠梗塞体积和脑水肿。原花青素B2 (40mg / kg, 口服) 也改善功能结果, 调节脑缺血后的血脑屏障 (BBB) 通透性。此外, 原花青素B2减轻脑缺血诱导的紧密连接降解, 线粒体去极化和细胞内氧化应激。原花青素B2 (40 mg / kg, po) 可增加体内正常大脑中Nrf2的活化和HO-1, GSTα和NQO1蛋白的表达[3]。 |
| SMILES | O[C@H]1[C@@H](C2=CC=C(O)C(O)=C2)OC3=CC(O)=CC(O)=C3[C@@H]1C4=C5C(C[C@@H](O)[C@@H](C6=CC=C(O)C(O)=C6)O5)=C(O)C=C4O |
| 靶点 | Reactive oxygen species (ROS) |
| 动物实验 | 为了观察原花青素B2对梗死面积或脑水肿的影响, 将40只大鼠随机分成5组, 每组给予载体 (通过管饲法施用相当剂量的0.9％盐水) 或40, 20或10mg /分别为kg的原花青素B2。为了阐明原花青素B2对血脑屏障 (BBB) 通透性的影响, 大鼠 (伊文思蓝外渗每组n = 6, IgG组泄漏每组n = 4) 随机分为两组：载体和原花青素B2 (40毫克/千克) 。从大脑中动脉闭塞 (MCAO) 后3小时开始, 每天一次胃内施用原花青素B2 (40mg / kg) 。对于其他观察, 包括免疫组织学染色和蛋白质印迹分析, 将大鼠随机分成三组：假手术, 载体和原花青素B2 (每组n = 4) 。从MCAO后3小时开始, 每天一次胃内施用原花青素B2 (40mg / kg) 。为了阐明大鼠缺血性中风后神经功能的改善, 大鼠 (每组n = 8) 进行神经行为测定以评估在MCAO后24小时开始每天一次施用原花青素B2 (40mg / kg) 后的功能结果。 。在MCAO后1, 3, 7, 11和14天评估神经功能缺损[3]。 |
| 细胞实验 | 使MCF-7细胞在5mL补充有20％胎牛血清, 青霉素 (100U / mL) 和链霉素 (100μg/ mL) 的RPMI 1640培养基中生长。将细胞保持在37℃, 5％CO 2的空气湿润气氛中, 每3天传代培养。将指数生长的细胞以2×10 4个细胞/ mL的接种密度接种在96孔板或培养皿中。在孵育过夜以允许附着后, 将细胞暴露24或48小时至在蒸馏水中稀释的各种浓度的原花青素B2 (0.5; 1.0; 5.0; 10.0; 25.0和50.0μM) 。使用2毫摩尔环磷酰胺 (CP) 作为阳性对照, 并通过过滤对溶液进行灭菌[1]。 |
| 数据来源文献 | [1]. Avelar MM, et al. Procyanidin b2 cytotoxicity to mcf-7 human breast adenocarcinoma cells. Indian J Pharm Sci. 2012 Jul; 74 (4) :351-5.
[2]. Yang H, et al. Procyanidin B2 inhibits NLRP3 inflammasome activation in human vascular endothelial cells. Biochem Pharmacol. 2014 Dec 15; 92 (4) :599-606. [3]. Wu S, et al. Procyanidin B2 attenuates neurological deficits and blood-brain barrier disruption in a rat model of cerebral ischemia. Mol Nutr Food Res. 2015 Oct; 59 (10) :1930-41. |
| 备注 | 以上数据均来自公开文献, Jinpan暂未进行独立验证, 仅供参考。These protocols are for reference only. Jinpan does not independently validate these methods. |
| 规格 | 5mg 10mg |
Procyanidin B2 是一种黄酮类物质，具有抗肿瘤，抗氧化等活性。
泰林HTY滤膜孔径测定仪 产品特点：
HTY滤膜孔径测定仪，系本公司自主开发的
微孔滤膜专用测试仪器，可对0.22μm、0.45μm.0.8μm等
孔径规格的亲水及油性微孔滤膜进行检测。
— 适用范围：
可广泛应用于滤膜生产和使用单位，
用于滤膜质量的检测和控制。
| 商品属性 | |
|---|---|
| 商品名称 | 泰林HTY滤膜孔径测定仪-HTY-泰林 |
| 型号 | HTY |
| 类别 | 生命科学仪器|||微生物学|||滤膜孔径测定仪|||泰林HTY滤膜孔径测定仪 |
| 品牌 | 泰林 |
| 品牌简介 | 泰林 |
| 关键字 | 滤膜孔径测定仪,滤膜,孔径,读数,微孔,测量,最小 |
【简单介绍】
【简单介绍】
【详细说明】
上海金畔生物科技有限公司
文章号：20604630-20604630
VML-295CAS号： 161172-51-6分子式： C33H33FO6分子量： 544.61描述应用储存/保存方法形态外观沸点可溶性/溶解性PubChem CID
| 产品描述 | |
| 描述 |
LY293111 is a potent antagonist of leukotrine B4 repector (BLT1) which inhibits the specific binding of radiolabeled-LTB4 to this receptor (IC50 = 17.6 nM). This further prevents LTB4-induced chemotaxis of neutrophils (IC50 = 6.3 nM). Additional in vitro studies have shown that LY293111 inhibits growth of MiaPaCa-2 and AsPC-1 cell lines and subcutaneous xenografts by inducing apoptosis and S-phase arrest.
|
| 应用 |
A BLT1 antagonist
|
| 储存/保存方法 |
Store at -20° C
|
| 形态 |
Liquid
|
| 基本信息 | |
| 外观 |
Solution
|
| 沸点 |
57° C
|
| 可溶性/溶解性 |
Soluble in water, ethanol, DMF and DMSO
|
| PubChem CID |
177941
|
5-溴-4-氯-3-吲哚基-磷酸二钠盐BCIP
货号：BS151-100mg
规格：100mg
品牌： Jinpan
| 货号 | BS151-100mg |
| 规格 | 100mg |
| 品牌 | Jinpan |
| 说明书下载 | 点击下载 |
Mabtech peptide pools
Mabtech是一家瑞典生物科技公司，创办于1986年，公司核心业务是致力于优化发展酶联免疫斑点法技术 (ELISpot)、荧光免疫斑点法技术 (FluoroSpot) 和酶联免疫吸附试验技术 (ELISA) 等免疫学方法。Mabtech开发的肽库可以作为T细胞的抗原特异性阳性对照，且所有肽库都经过验证，都可用于ELISpot、FluoroSpot和流式细胞术。
1. CEF peptide pool for human CD8 T cells
CEF肽库刺激CD8 + T细胞优先产生IFN-γ。
CEF肽库由分别来自人CMV、EBV和流感病毒的23个MHC I型限制性病毒肽组成。它已被证明在近90%的高加索人中诱导IFN-γ反应。
CEF肽库(Cat#3616-1)刺激人外周血单个核细胞，使用ELISpot检测分泌的Granzyme B。
CEF肽库(Cat#3616-1)和抗人CD28抗体刺激人外周血单个核细胞，使用FluoroSpot检测IFN-γ/ Granzyme B。
|
产品名称 |
规格 |
货号 |
|
CEF peptide pool for human CD8 T cells |
23x 25 µg |
3616-1 |
2. CEFTA peptide pool for human CD4 T cells
CEFTA肽库刺激人CD4 + T细胞产生IFN-γ、IL-2、IL-5和IL-13。
CEFTA肽库由分别来自人CMV、EBV、流感病毒、破伤风毒素和腺病毒5的35个MHC II型限制性病毒肽组成。它被设计成用大批的HLA类型刺激T细胞。合成肽纯度>95%。
CEFTA肽库(Cat#3617-1)刺激人外周血单个核细胞后，使用ELISpot检测分泌的IFN-γ。
CEFTA肽库(Cat#3617-1)刺激人外周血单个核细胞后，用FluoroSpot检测分泌的IFN-γ/IL-5。
在有布雷非德菌素A条件下，CEFTA肽库和抗CD28抗体刺激人外周血单个核细胞。CEFTA肽库刺激后CD4+细胞表达IFN-γ而CD8+细胞没有表达。细胞经CD3-BV421和CD4-FITC和CD8-PE染色后，用4%多聚甲醛和皂苷进行固定和渗透。
|
产品名称 |
规格 |
货号 |
|
CEFTA peptide pool for human CD4 T cells |
35 x 25 µg |
3617-1 |
3. CEF extended peptide pool for human CD8 T cells
CEF扩展肽库刺激CD8+ T细胞产生IFN-γ、IL-2和Granzyme B。
CEF扩展肽库由分别来自人CMV、EBV和流感病毒的32个MHC I型限制性病毒肽组成。
CEF扩展肽库(Cat#3618-1)刺激人外周血单个核细胞，使用ELISpot检测分泌的IFN-γ。
CEF扩展肽库(Cat#3618-1)刺激人外周血单个核细胞，使用FluoroSpot检测分泌的IFN-γ。
在有布雷非德菌素A条件下，CEF扩展肽库（2 ug/ml）和抗CD28抗体(0.1 ug/ml)刺激人外周血单个核细胞16小时。CEF扩展肽库刺激后CD8+细胞开始表达IFN-γ，而CD4+ 细胞没有表达。细胞经CD4-PE和CD8-FITC染色后，再用4%多聚甲醛和皂苷进行固定和渗透。
|
产品名称 |
规格 |
货号 |
|
CEF extended peptide pool for human CD8 T cells |
32 x 25 µg |
3618-1 |
4. CMV peptide pool for human CD4 and CD8 T cell
CMV肽库刺激CD4+和CD8+ T细胞产生IFN-γ、、IL-2、IL-5和IL-13。
CMV肽库包含42个巨细胞病毒多肽。肽库中的抗原为pp50、pp65、IE1、IE2和包膜糖蛋白b。28个肽段为MHC I型限制性肽段，14个为MHC II型限制性肽段。合成肽的纯度>95%。
CMV肽库(Cat#3619-1)刺激人外周血单个核细胞，使用ELISpot检测分泌的IFN-γ。
CMV肽库(Cat#3619-1)刺激人外周血单个核细胞，使用FluoroSpot检测分泌的IFN-γ和IL-2。
在有布雷非德菌素A条件下，CMV肽库(2 ug/ml)和抗CD28抗体(0.1 ug/ml)刺激人外周血单个核细胞16小时。左图中CMV肽库刺激后CD4+细胞开始表达IFN-γ，右图中IFN-γ由CD8+细胞产生。细胞经CD4-PE和CD8-FITC染色后，再用4%多聚甲醛和皂苷进行固定和渗透。
|
产品名称 |
规格 |
货号 |
|
CMV peptide pool for human CD4 and CD8 T cells |
42x 25 µg |
3619-1 |
详情请咨询Mabtech全国代理-上海金畔生物科技
【简单介绍】
